Inventor profile of:

Gary E. Borodic

City:

Canton, Massachusetts

Country:

United States

Published Applications:

38

Last publication date:

2024-06-13

Top Assignees for applications by Gary E. Borodic

The entities that hold a legal rights for patent applications filed by inventor Borodic Gary E.:

Recent patent applications by Borodic Gary E.

Gary E. Borodic from Canton, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-06-13
US20240189402A1
Human necessities

Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

#2 | 2024-04-04
US20240108700A1
Human necessities

Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s)

#3 | 2024-03-28
US20240100135A1
Human necessities

Methods of Treating an Optic Disease in a Subject

#4 | 2024-01-04
US20240000906A1
Human necessities

Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s)

#5 | 2023-12-07
US20230390368A1
Human necessities

Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)

#6 | 2021-10-07
US20210308236A1
Human necessities

BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT

#7 | 2021-09-16
US20210283228A1
Human necessities

BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT

#8 | 2021-08-19
US20210252116A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#9 | 2020-11-26
US20200368331A1
Human necessities

Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

#10 | 2020-03-12
US20200078450A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#11 | 2020-02-13
US20200046813A1
Human necessities

Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

#12 | 2019-12-19
US20190381152A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#13 | 2018-12-06
US20180344806A1
Human necessities

Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

#14 | 2018-10-25
US20180303917A1
Human necessities

Method of treating macular degeneration using botulinum toxin-based pharmaceuticals

#15 | 2018-10-18
US20180296651A1
Human necessities

Method of treating macular degeneration using botulinum toxin-based pharmaceuticals

#16 | 2018-06-14
US20180161407A1
Human necessities

Method of treating macular degeneration using botulinum toxin-based pharmaceuticals

#17 | 2017-11-23
US20170333537A9
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#18 | 2017-11-09
US20170319667A9
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#19 | 2017-09-07
US20170252415A9
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#20 | 2017-06-15
US20170165331A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#21 | 2017-06-15
US20170165330A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#22 | 2017-05-25
US20170143807A9
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#23 | 2016-02-25
US20160051643A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#24 | 2016-02-18
US20160045577A1
Human necessities

Botulinum toxin and the treatment of primary disorders of mood and affect

#25 | 2015-10-22
US20150297688A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#26 | 2015-09-17
US20150258183A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#27 | 2015-05-14
US20150132283A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#28 | 2015-03-26
US20150086533A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#29 | 2015-03-26
US20150086532A1
Human necessities

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

#30 | 2014-10-23
US20140315820A1
Chemistry; metallurgy

High-Potency Botulinum Toxin Formulations

#31 | 2010-11-04
US20100279945A1
Chemistry; metallurgy

High-potency botulinum toxin formulations

#32 | 2010-11-04
US20100278867A1
Human necessities

Use of botulinum toxin for the treatment of chronic facial pain

#33 | 2009-06-11
US20090148476A1
Human necessities

Anti-inflammatory topical botulinum toxin composition

#34 | 2009-05-26
US9382837
-

Chemodenervating pharmaceutical as anti-inflammatory agent

#35 | 2007-01-11
US20070009555A1
Human necessities

Botulinum toxin and the treatment of primary disorders of mood and affect

#36 | 2006-08-17
US20060182767A1
Chemistry; metallurgy

High-potency botulinum toxin formulations

#37 | 2006-07-06
US20060147471A1
Human necessities

Compositions, methods and devices for preparing less painful Botulinum toxin formulations

#38 | 2005-09-22
US20050208075A1
Human necessities

Methods of using toxin for the treatment of hypervolemic lip deformity (lip ectropion)

InventorID:

945613 ⎘